Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

2024

Base Year

2018-2024

Historical Year

2025-2034

Forecast Year

Ischemic Heart Disease Drugs Market Size

The ischemic heart disease drugs market was valued at USD 4.94 billion in 2024, driven by the rising incidence of heart diseases across the globe. The market is expected to grow at a CAGR of 4.35% during the forecast period of 2025-2034, with the values likely to attain USD 6.87 billion by 2034.

Ischemic Heart Disease Drugs Market Outlook

  • In March 2024, the U.S. FDA approved Wegovy (semaglutide) injection, expanding its use to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease.
  • In December 2023, the FDA approved colchicine for the prevention of heart disease. Colchicine, previously Lodoco, is now prescribed to supplement cholesterol and blood pressure medications in reducing the risk of heart disease and stroke. Such decisions by regulatory authorities is expected to impact the market positively.
  • Causing 108.8 deaths per 100,000 people ischemic heart disease is a major cause of CVD deaths worldwide. Increasing incidence of the condition is propelling the market demand for ischemic heart disease drugs.

Ischemic Heart Disease Drugs Market Overview

Ischemic heart diseases are medical conditions under which the patient’s heart arteries that supply blood to the heart muscle get narrowed, lowering the blood flow. In severe cases, the patient suffers from artery blockage which is then treated surgically (if feasible). To improve the blood flow in such medical conditions, ischemic heart disease drugs are prescribed to patients. The market is expected to witness substantial growth due to the increasing prevalence of heart diseases worldwide. With the increasing prevalence, the increasing demand for ischemic heart disease drugs is corresponding.

Ischemic Heart Disease Drugs Market Growth Factors

Prevalence of Heart Diseases Boosting the Market Demand

The increasing prevalence of cardiovascular diseases is contributing to the increased demand for ischemic heart disease drugs. According to the new Global Burden of Disease (GBD) special report published in 2023, ischemic heart disease is the leading cause of death for cardiovascular disease worldwide. It causes 108.8 deaths per 100,000 people. Estimated by the Centers for Disease Control and Prevention nearly 805,000 people suffer from a heart attack every year in the United States. As a result, the demand for effective therapeutics is on the rise.

Rising Approvals by the Regulatory Authorities to Meet the Ischemic Heart Disease Drugs Market Demand

In March 2024, the U.S. Food and Drug Administration gave clearance to Wegovy (semaglutide) injection, expanding its use to reduce the risk of cardiovascular death, heart attack, and stroke in overweight or obese adults. This approval marks a significant advancement in the management of ischemic heart disease, particularly for patients at higher risk due to their weight. Wegovy is an established medication for weight management that is now additionally useful in the treatment of obesity with direct cardiovascular benefits, potentially transforming the therapeutic landscape for ischemic heart disease. The approval was based on a robust, multi-national, placebo-controlled double-blind trial involving over 17,600 participants, reinforcing the drug's efficacy and safety. This development is expected to drive increased adoption of Wegovy in cardiovascular risk management, leading to increased market penetration and potentially stimulating further research and development in cardio-metabolic drugs. Consequently, the ischemic heart disease drugs market is likely to witness significant growth, with enhanced treatment options that address both the symptoms of heart disease and risk factors such as obesity.

In December 2023, the FDA approved colchicine drug (traditionally used for gout and other inflammatory conditions) for the prevention of heart disease as well. Previously Lodoco, colchicine was approved recently to manage cholesterol levels, and blood pressure and reduce the risk of heart disease and stroke. This approval marked a significant expansion in the use of colchicine, positioning it as a potential drug in ischemic heart disease management. This approval could potentially trigger increased clinical research and investment for the repurposing of other existing drugs for cardiovascular indications, boosting the market growth.

Regulatory Authorities Expanding the Application of Drug

In March 2024, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) has approved the expansion of Praluent® (alirocumab) usage to include pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). This approval marks a significant expansion in the treatment landscape for ischemic heart disease, as Praluent, targeting the PCSK9 enzyme, becomes one of the few therapies available to younger patients at high genetic risk of heart disease. With the expanded usage of Praluent, it will now be helpful in treating heart disease in early diagnosis and effectively managing the condition in the long term. Consequently, the market is poised for substantial growth.

Ischemic Heart Disease Drugs Market Trends

Key Trend Impact
Increasing Prevalence of Cardiovascular Diseases The market is witnessing a growing geriatric population, susceptible to ischemic heart diseases. The increasing geriatric population is contributing to the increasing prevalence of the ischemic heart disease IHD worldwide.
Advancements in Drug Development With increasing advancements in drug development, the market is witnessing a significant shift towards personalised medicine in the treatment of IHD.
Advent of Biologics and Novel Drugs Molecules The market is experiencing a significant shift towards the development of biologics and novel small-molecule drugs offering innovative treatments.
Increasing Emphasis on Early Prevention Increasing demand for medication that curbs or manages the occurrence of risk factors leading to IHDs is driving the market growth. The demand for blood pressure and cholesterol management drugs is consistent.


Ischemic Heart Disease Drugs Market Segmentation

Market Breakup by Disease Type

  • Angina Pectoris
  • Myocardial Infarction

Market Breakup by Drug Class
 

  • Anti-Dyslipidemic Drugs
  • Calcium Channel Blockers
  • Beta-Blockers
  • ACE Inhibitors
  • ARBs
  • Vasodilators
  • Antithrombotic Agents

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

Ischemic Heart Disease Drugs Market Share

Angina Pectoris Leads the Market Segmentation Based on Disease Type

The market share based on disease type includes angina pectoris and myocardial infarction. The angina pectoris segment is expected to lead the market due to its high prevalence. Angina is a symptom of coronary artery disease in which chest pain is experienced by the patient due to reduced blood flow to the heart muscles. Frequent encounters drive demand for drugs to provide relief and improve patient’s quality of life.

Market Segmentation Based on Drug Class to Witness Substantial Growth

The drug class segmentation includes anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic agents. The drug class segmentation is dominated by anti-dyslipidemic drugs as management of blood lipid levels is necessary to avoid and treat ischemic heart diseases (IHD). These drugs include statins, fibrates, and cholesterol absorption inhibitors that are considered effective in reducing cholesterol levels. It is particularly effective in managing bad cholesterol LDL, a major risk factor for the formation of plaques in the arteries.

Ischemic Heart Disease Drugs Market Analysis by Region

Based on the regions, the market report covers the United States, EU-4 (Germany, France, Italy, Spain) and the United Kingdom, Japan and India, with each region contributing to the overall dynamics of the market. United States is leading the market share with the presence of a robust healthcare infrastructure to provide high-end treatments to patients. The increasing prevalence of people suffering from heart diseases such as coronary artery disease (CAD), arrhythmias, cardiomyopathy, and valvular heart diseases, among others is collectively driving the demand for ischemic heart disease drugs in the region. Data from the Centers for Disease Control and Prevention states that in the United States, every 33 seconds cardiovascular disease claims a human life. The annual expenditure on heart disease amounted to USD 239.9 billion from 2018 to 2019.

Leading Players in the Ischemic Heart Disease Drugs Market

The key features of the market report include patent analysis, clinical trials analysis, grants, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Eli Lilly and Company

Eli Lilly and Company was established in 1876 and is currently headquartered in Indianapolis, Indiana, USA. The company is focused on developing and distributing effective medications for various including endocrinology, oncology, immunology, neuroscience, and cardiovascular diseases.

Bayer AG

Founded in 1863, Bayer AG is a prominent pharmaceutical company focused on cardiology, hematology and oncology related prescription drugs. Some notable products in the cardiovascular domain include aspirin, Xarelto (rivaroxaban), and Eylea (aflibercept) among others.

Pfizer Inc.

Headquartered in New York, USA, this company was established in 1849. The company has a strong product portfolio of cardiovascular diseases as well as continuously takes part in research initiatives for providing a diverse range of medications to consumers.

Other players in the market include Sanofi, Novartis AG, Baxter International, Inc., Merck & Co., Inc., Johnson & JohnsonServices, Inc., Amgen Inc., Boehringer Ingelheim International GmbH

F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Bristol-Myers Squibb Company, and Eisai Co., Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report. 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2018-2024
Forecast Period 2025-2034
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease
  • Drug Class
  • Distribution Channel
  • Region
Breakup by Disease
  • Angina Pectoris
  • Myocardial Infarction
Breakup by Drug Class
  • Anti-Dyslipidemic Drugs
  • Calcium Channel Blockers
  • Beta-Blockers
  • ACE Inhibitors
  • ARBs
  • Vasodilators
  • Antithrombotic Agents
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Eli Lilly and Company
  • Bayer AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Novartis AG
  • Baxter International, Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH 
  • F. Hoffmann-La Roche AG 
  • GlaxoSmithKline plc 
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd. 

Key Queries Solved in the Ischemic Heart Disease Drugs Market Report

  • What was the ischemic heart disease drugs market value in 2023?  
  • What is the ischemic heart disease drugs market forecast outlook for 2025-2034?  
  • What are the major factors aiding the global market demand?  
  • What are the major market trends? 
  • What is the market segmentation based on the disease type?
  • What is the market segmentation based on the distribution channel?
  • What is the market breakup by drug class?
  • What are the major markets according to the EMR report? 
  • Who are the key players involved in the ischemic heart disease drugs market?
  • How will the market landscape evolve in the upcoming years? 
  • What are the major drivers, opportunities, and restraints in the market? 
  • What will be the effect of each driver, challenge, and opportunity on the market? 
  • Which country is poised to lead the market share in the forecast period? 
  • Which segment has the highest impact on the market size? 
  • How are partnerships, collaborations, mergers and acquisitions shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Datasheet

10 % Off

USD

3,299

2,969

Single User License

10 % Off

USD

5,499

4,969

Five User License

15 % Off

USD

6,999

5,949

Corporate License

15 % Off

USD

8,199

6,969

Datasheet

One User

USD 3,299

USD 2,969

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 5,499

USD 4,969

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 8,199

USD 6,969

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124